SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending as the biotech sector (XBI) continues its surprising upward momentum, pushing past anticipated resistance levels and fueling intense debate among investors who see unsustainable technicals and await a significant correction. The community is actively discussing whether XBI's prolonged rally is nearing a reversal point, as broader market uncertainty and recent biotech buyouts contribute to a complex outlook.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as the biotech sector sees a robust rally, driven by optimistic outlooks on AI advancements in drug discovery and anticipation of Fed rate cuts, while investors actively debate the sustainability of this strong upward momentum.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending amidst high anticipation for its merger with quantum technology leader Infleqtion, poised to debut on the NYSE as INFQ. The exceptionally low redemption rate signals strong investor confidence, with the community actively discussing Infleqtion's "best in class" quantum computing and sensing capabilities, bolstered by significant government contracts.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending as activist investor Elliott Management reportedly built a significant stake, aiming to drive changes and help the company catch up with rivals. This news is generating excitement among investors hopeful for operational improvements and a rebound, though some remain cautious amid ongoing debate around the recent CEO transition and perceived market manipulation.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is trending as Hapag-Lloyd has announced a definitive agreement to acquire the company for $35 per share, generating excitement around the significant premium and potential for a short squeeze. The community is actively discussing the deal's finalization, anticipating regulatory approval from the Israeli government, and speculating on potential dividends until the expected late 2026 closing.

Parsons Corp. is a disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and intelligence, space and missile defense, transportation, environmental remediation, urban development, and critical infrastructure protection. It operates through the Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is involved in advanced technologies, including cybersecurity, missile defense systems, C5ISR, space launch and situational awareness, geospatial intelligence, RF signals intelligence, nuclear and chemical waste remediation, and engineering services. The Critical Infrastructure segment offers integrated design and engineering services for complex physical and digital infrastructure around the globe. The company was founded by Ralph Monroe Parsons on June 12, 1944 and is headquartered in Chantilly, VA.

Parsons Corp

Parsons is trending after losing a major FAA contract and facing renewed uncertainty around a confidential federal program, amplified by broader market concerns over government spending efficiency. However, many in the community view the sharp pullback as an oversold buying opportunity, highlighting the company's extensive backlog and robust position in critical infrastructure, cyber, and defense sectors.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors react to its recent earnings, which featured optimistic guidance and strategic job cuts aimed at boosting margins by reducing Amazon volume. This positive outlook is being weighed against immediate concerns surrounding a fatal cargo plane crash and subsequent aircraft groundings, sparking community discussion over long-term strategy, operational risks, and the stock's dividend appeal.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

VXX is trending as market participants anticipate a potential volatility spike, fueled by ongoing geopolitical tensions, upcoming economic releases, and Q3 earnings reports, leading many to position for a significant market pullback while others caution against holding volatility products long-term due to decay.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending due to its strategic acquisition of Diligent Robotics, expanding its autonomous platform into the healthcare sector, which is bolstered by recent bullish analyst coverage and Nvidia CEO Jensen Huang's public endorsement. This is driving community discussion around its 'Physical AI' growth potential amidst ongoing questions about valuation and profitability.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience is generating significant conversation following its NASDAQ listing and recent capital raise, with community members divided over the prospects of its lead Duchenne Muscular Dystrophy (DMD) drug, SAT-3247. While some investors see its novel muscle regeneration mechanism and anticipated Phase 2 data as a potential breakthrough, others express skepticism concerning financial actions and the inherent challenges of developing early-stage biopharma treatments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Equity

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.


Nasdaq-listed shares of UK-based TC BioPharm (Holdings) PLC (TCBP) tumbled 64% by Friday afternoon after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tcbp-announces-transition-from-nasdaq-to-otc-markets-302408102.html">said</a> its securities would be delisted from the exchange.The delisting follows the company’s failure to maintain a minimum bid price of $1 per share. The company said that its management is working on an appeal with Nasdaq and expressed optimism that its American Depositary Shares will be eligible to trade on the OTC markets starting Monday.Earlier this week, the company announced a reduction in its workforce and other measures aimed at reducing core operational burn by 55% compared to last year. The layoff impacted approximately 20 employees, or <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tcbiopharm.com/news/press-releases/detail/122/tcbp-announces-outsourcing-initiatives-reducing-burn-rate">half of the company’s total headcount</a>.On Stocktwits, investors expressed frustration over the news.&nbsp;<stembedurl>https://stocktwits.com/Blackdog111/message/608838652</stembedurl>One user opined that there is little chance for recovery for the company’s stock.<stembedurl>https://stocktwits.com/Oxinternet/message/608832026</stembedurl>In early March, TC BioPharm announced that it had executed a non-binding letter of intent to acquire 100% of a commercial-stage ophthalmic pharmaceutical company in an all-stock transaction.CEO Bryan Kobel said the firm expects to execute the binding letter of intent in a few weeks and close the acquisition around the third quarter of this year.At the beginning of 2025, Kobel <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/tcbp-issues-25-stock-dividend-302340235.html">said</a> he anticipated 2025 to be a “period of growth and development” for the company. He expressed “strong confidence” in the company’s financial future after issuing a special dividend of 0.25 &nbsp;American Depositary Shares (ADSs) for every ADS held by shareholders.&nbsp;The stock has dropped by over 94% this year, wiping nearly all its value over the past twelve months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rio-tinto-eyes-bigger-us-footprint-amid-copper-price-surge-fueled-by-trump-tariffs/ch7oTeGRb53">Rio Tinto Reportedly Eyes Bigger US Footprint Amid Copper Price Surge Fueled By Trump Tariffs – Stock Drops, Retail Sentiment Weakens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

TC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses Frustration

The company said that its management is working on an appeal with Nasdaq and expressed optimism that its American Depositary Shares will be eligible to trade on the OTC markets starting Monday.

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

TC BioPharm (Holdings) plc - ADR

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$0.05
Prev Close	$0.05
Open	$0.05
Dividend Yield	0.00%
50-Day Moving Average	$0.0953
Beta	0.05
Avg. Volume	14,056.00
PE Ratio	0.00

52-Week High	$2.69
52-Week Low	$0.03
Market Capitalization	$31,900.00
EPS (Annual)	-$164.58
Price to Book	0.03
Revenue Per Employee	$0.00

TCBP
TC BioPharm Holdings Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest TCBP News

TCBPTC BioPharm Holdings Ltd